Modality
ASO
MOA
CAR-T CD19
Target
B7-H3
Pathway
STING
RCCNASH
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
Oct 2018
→ May 2030
Phase 2Current
NCT07278194
2,934 pts·NASH
2018-10→TBD·Terminated
NCT03825744
2,435 pts·RCC
2023-01→2030-05·Active
5,369 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-174.1y awayPh3 Readout· RCC
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2/3
Termina…
P2/3
Active
Catalysts
Ph3 Readout
2030-05-17 · 4.1y away
RCC
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07278194 | Phase 2/3 | NASH | Terminated | 2934 | UPCR |
| NCT03825744 | Phase 2/3 | RCC | Active | 2435 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 |